Related Experiment Videos
[Apache III score: a prognostic factor in pressure ulcer development in an intensive care unit]
D Almirall Solsona1, A Leiva Rus, I Gabasa Puig
1Unidad de Cuidados Intensivos, Hospital General de Vic, Vic, Barcelona, España. almirallsolsona@hotmail.com
Unlabelled:
OBJECTIVE. To analyze total APACHE III score association to pressure ulcers development in patients hospitalized in an intensive care unit (ICU).
Material And Methods:
Prospective cohort study conducted in an intensive care unit of the Hospital General de VIC. All the patients hospitalized between January 2001 to December 2001 were enrolled. Age, gender, length of stay, total Norton and APACHE III score and pressure sore development were collected.
Results:
Pressure sore incidence was 12.5% of the patients. The factors were significantly associated with the appearance of pressure sores in those patients with a length of stay in the intensive care unit, total Norton and severity of the disease measured by the APACHE III score. Patients having the greatest risk of pressure ulcers development were those whose Norton score was less than or equal to 14, and an APACHE III score higher than or equal to 50 (Odds Ratio: 37.9, 95% CI 11.16-128.47)
Conclusion:
The severity of the diseases measured with the APACHE III scale showed a relationship with the appearance of in-hospital pressure ulcers. The joint use of the APACHE III and Norton scale could be a good strategy to detect patients with very high risk of suffering pressure sores.
Related Concept Videos
Peripheral Artery Disease IV: Nursing Management
Peptic Ulcer
Diabetic Foot Ulcer
Peripheral Artery Disease V: Postoperative Nursing Management
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease III: Clinical Manifestations and Complications